H.C. Wainwright notes that Neutral-rated Cassava Sciences (SAVA) has announced its financial and operational results for the fiscal year ended ...
Hosted on MSN15d
Key form of tau protein identified for understanding and treating Alzheimer's diseaseAlzheimer's & Dementia (2025). DOI: 10.1002/alz.14403, alz-journals.onlinelibrary.wil … ll/10.1002/alz.14403 Provided by University of Cologne ...
For information, education, referrals, or support, call the Alzheimer’s Association 24/7 helpline at 1-800-272-3900 or visit their website at alz.org. The Wyoming Center on Aging in collaboration with ...
Cassava is preparing to report the topline results of the now-discontinued REFOCUS-ALZ, the second Phase 3 study of simufilam in Alzheimer’s ...
Top-line data for REFOCUS-ALZ, the second Phase 3 study of simufilam in Alzheimer’s disease, expected late first-quarter/early second-quarter 2025 License agreement brings potential in a new ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
TORONTO, January 31, 2025--Cboe Canada is proud to welcome back CIBC as they expand their suite of CDRs to include European markets with the listing of five CDR tickers.
The following resolution were passed at the extraordinary general meeting (the "EGM") of Alzinova AB (publ) ("the Company") on 7 March 2025 in Gothenburg. Long-term incentive program (LTIP 2025:1 for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results